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Abstract
Class I MAGE proteins (MAGE I) are normally expressed only in developing germ cells but are aberrantly expressed in many
cancers. They have been shown to promote tumor survival, aggressive growth, and chemoresistance but the underlying
mechanisms and MAGE I functions have not been fully elucidated. KRAB domain zinc finger transcription factors (KZNFs) are
the largest group of vertebrate transcription factors and regulate neoplastic transformation, tumor suppression, cellular
proliferation, and apoptosis. KZNFs bind the KAP1 protein and direct KAP1 to specific DNA sequences where it suppresses
gene expression by inducing localized heterochromatin characterized by histone 3 lysine 9 trimethylation (H3me3K9).
Discovery that MAGE I proteins also bind to KAP1 prompted us to investigate whether MAGE I can affect KZNF and KAP1
mediated gene regulation. We found that expression of MAGE I proteins, MAGE-A3 or MAGE-C2, relieved repression of a
reporter gene by ZNF382, a KZNF with tumor suppressor activity. ChIP of MAGE I (-) HEK293T cells showed KAP1 and
H3me3K9 are normally bound to the ID1 gene, a target of ZNF382, but that binding is greatly reduced in the presence of
MAGE I proteins. MAGE I expression relieved KAP1 mediated ID1 repression, causing increased expression of ID1 mRNA and
ID1 chromatin relaxation characterized by loss of H3me3K9. MAGE I binding to KAP1 also induced ZNF382 poly-
ubiquitination and degradation, consistent with loss of ZNF382 leading to decreased KAP1 binding to ID1. In contrast, MAGE
I expression caused increased KAP1 binding to Ki67, another KAP1 target gene, with increased H3me3K9 and decreased Ki67
mRNA expression. Since KZNFs are required to direct KAP1 to specific genes, these results show that MAGE I proteins can
differentially regulate members of the KZNF family and KAP1 mediated gene repression.
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Introduction
Class I MAGE proteins (MAGE I) are normally expressed only
in developing germ cells, trophoblast and placenta because their
expression is suppressed in somatic tissues by hypermethylation of
promoter region CpG dinucleotide islands [1] [2,3]. In cancers,
however, MAGE I may be aberrantly expressed because of global
hypomethylation that often occurs during epigenetic reprogram-
ming [2,3]. Because MAGE I expression post utero is limited to
developing sperm and cancers, MAGE I proteins have been used
extensively as targets for anti-tumor antibodies and cancer
vaccines[4] but the functional contributions of MAGE I to
oncogenesis and the mechanisms involved have been relatively
understudied.
MAGE I expression in malignancies has been correlated with
aggressive clinical course, the acquisition of resistance to
chemotherapy, and poor clinical outcome [1,5,6,7,8,9]. We have
shown that suppression of MAGE I decreases the growth of
melanoma and malignant mast cell lines in vitro and in vivo [10–11],
and Liu et al [12] have shown that MAGE I expression causes
accelerated cell cycle progression, increases the rate of cell
migration and invasion in vitro, and increases lung metastases in
an orthotopic mouse model of human thyroid cancer. We and
others have found that MAGE I proteins bind to the RBCC region
of KAP1[11,13], a scaffolding protein whose functions include:
(1). suppression of p53 by increasing KAP1 ubiquitin E3 ligase
activity and p53 ubiquitination [9,11,13]. (2). global induction
and maintenance of transcriptionally inactive heterochromatin
characterized by Histone 3 tri-methyl lysine 9 (H3me3K9), and
(3). suppression of specific genes by localized induction of
transcriptionally inactive heterchromatin, targeted by KRAB
domain containing zinc finger transcription factors (KZNFs).
The KZNFs are the largest group of transcription factors known
in vertebrates, and are involved in cell differentiation, prolifera-
tion, apoptosis, tumor suppression, and neoplastic transformation
[14,15] [16]. For instance ZNF382, a KZNF also known as KS1,
has recently been identified as a tumor suppressor controlling a
number of oncogenes including ID1 [16]. KZNFs bind to the
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DNA sequences through their zinc fingers, thereby guiding KAP1
to repress specific genes by inducing H3me3K9 and causing
localized chromatin compaction. Our discovery that MAGE I
proteins bind to the same KAP1 RBCC region as KZNFs [11]
prompted us to investigate whether MAGE I can affect KZNF and
KAP1 mediated gene regulation. Using an integrated reporter
gene construct in CHO cells we show here that representatives of
two large MAGE I families, MAGE-A3 and MAGE-C2, can de-
repress KAP1 mediated gene silencing by ZNF382. In HEK293T
cells, MAGE I expression decreases KAP1 binding to the ID1
oncogene, a ZNF382 target, causing chromatin relaxation with
decreased H3me3K9 and increased ID1 mRNA expression.
MAGE I binding to KAP1 also induces ZNF382 poly-ubiquitina-
tion and degradation, suggesting the most likely mechanism is
degradation of ZNF382, leading to release of KAP1 from the
ZNF382 target site. In contrast, MAGE I expression increased
KAP1 binding to the Ki67 gene, causing increased H3me3K9 and
decreased Ki67 mRNA expression. Together, these data indicate
that MAGE I proteins can increase expression of some genes while
suppressing expression of others. Since KZNFs are required to
direct KAP1 to specific sites, this work shows that MAGE I
proteins can either positively or negatively regulate KZNF target
gene expression, and establish the ability of MAGE I proteins to
regulate members of the large and complex KZNF family.
Results
This work focuses on MAGE-A3 and MAGE-C2 as represen-
tatives of two major Class I MAGE families that they are often
expressed in human cancers. We will refer to them collectively as
‘‘MAGE I’’.
Confirmation of MAGE I and KAP1 binding sites
MAGE I have a large terminal exon that usually encodes the
entireproteinandcontainsthe MAGE homologydomain(MHD), a
conserved regionof ,170 amino acidsthat comprises about 70%of
each MAGE protein and that recently has been implicated as the
binding site for KAP1 [2,13]. To further characterize MAGE-
KAP1 interactions we developed constructs of the MAGE-A3 and
MAGE-C2 MHDs, and validated their ability to bind to KAP1 in a
modified mammalian two hybrid assay [17]. Using this assay, we
confirmed our previous findings showing strong binding between
Figure 1. MAGE-KAP1 binding decreases reporter gene repres-
sion by ZNF382. A. Full length MAGE-A3, full length MAGE-C2, or
corresponding MAGE homology domain constructs, bind to full length
KAP1 and RBCC-KAP1 detected by a Mammalian Two-Hybrid Assay.
CHO cells transfected with the indicated plasmids were assayed for
SEAP (secreted alkaline phosphatase) activity 48 h after transfection,
using a chemiluminescent substrate CSPD. pM3, pM53 and pVP16-T are
positive control vectors. pM and pVP16 are negative control vectors.
pVP16-KAP1 alone shows minimal light units. MHD = MAGE homology
domain. B. MAGE-A3 and MAGE-C2 decrease KAP1 repression of a
ZNF382 responsive reporter gene. Luciferase activities were measured
in CHO-5xGal4-UAS-TK-Luc-2p cells transfected with (+) control vector
(Gal4-DBD), with vector expressing full length (FL) MAGE-A3 or C2, or
with their corresponding MAGE homology domains (MHDs). Maximum
repression occurs in the presence of ZNF382 alone. Addition of MAGE
expression plasmids causes dose dependent release of repression with
increased luciferase activity. C. MAGE-C2 mutant L152A, L153A and
MAGE-A3 mutant L120A, L121A, which cannot bind KAP1, fail to relieve
repression mediated by ZNF382. D. MAGE-A3 and C2 mediated KAP1
repression of a ZNF382 responsive reporter gene is reversible. Addition
of ZNF382 expression plasmids initiate dose dependent regaining of
repression with decreased luciferase activity.
doi:10.1371/journal.pone.0023747.g001
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(p,0.05) (Figure 1A) [11]. We also found strong binding between
the MAGE-A3 and MAGE-C2 MHDs and the KAP1 RBCC
region, confirming and extending recently published results [13].
MAGE I alleviates ZNF382 and KAP1 mediated repression
of an integrated reporter gene
ZNF382, also known as KS1, is a KZNF that was recently
shown to be a tumor suppressor [16]. To determine the effects of
MAGE I expression on ZNF382 function and KAP1 mediated
gene repression we used the CHO-5xGal4-UAS-TK-Luc-2p cell
line which has limited expression of KAP1 and contains an
integrated fusion gene with an optimized binding site for ZNF382
at the 59 end of a constitutively active luciferase reporter gene
[18,19]. Ectopic expression of ZNF382 recruits KAP1 to the
reporter gene and suppresses luciferase expression. Figure 1B
shows that co-expression of full length MAGE-A3 or MAGE-C2
relieves ZNF382 mediated repression in a dose dependent
manner. Similar results are seen with the corresponding MHDs.
We also found that higher levels of expression of ZNF382
expression plasmids lead to dose-dependent recovery of repression
with decreased luciferase activity (Figure 1D). Interestingly,
mutated MAGE-C2
L152A,L153A and MAGE-A3
L120A,L121A, which
have decreased ability to bind KAP1 [13], were unable to relieve
ZNF382 induced repression (Figure 1C). Thus, effects of MAGE I
on KZNF mediated gene repression require MAGE I binding to
KAP1.
MAGE I attenuates KAP1 binding and repression of ID1,a
ZNF382 target
ZNF382 is ubiquitously expressed in normal tissues where it
causes localized chromatin compaction and represses several
oncogenes including ID1 [16]. Using ChIP with quantitative real
time PCR (qRT-PCR) targeting a unique KAP1 binding site in the
ID1 gene [20], we found that KAP1 is normally bound to the ID1
gene in MAGE I (-) HEK293T cells and is associated with
H3me3K9, indicating KAP1 induced chromatin compaction
(Figure. 2A, B). ID1 mRNA production is low in this state
(Figure 2D). As would be expected from our luciferase reporter
gene results, expression of MAGE I decreases KAP1 localization
to the ID1 gene (p,0.05), decreases chromatin compaction as
measured by H3me3K9 (p,0.05), and increases ID1 mRNA
expression (p,0.01) (Figure. 2A, 2B, 2D). Neither MAGE-A3 nor
MAGE-C2 localize to the ID1 gene (Figure 2C).
MAGE I enhances KAP1 binding and repression of Ki67
To determine whether other KAP1 targets might be affected by
MAGE I, we searched for KAP1 binding sites in a genome wide
KAP1 data base and found two sites in the Ki67 gene appropriate
Figure 2. MAGE I regulates KAP1 gene binding, trimethylation of histone 3 on lysine 9, and gene repression in HEK293T cells. MAGE
I expression decreases binding of KAP1, H3me3K9, and repression of the ID1 tumor suppressor gene (A, B, D). In contrast, MAGE I expression increases
binding of KAP1, H3me3K9, and repression of mRNA and protein levels of the Ki67 gene (E, F, H, I, J, L). Note MAGE I binds to Ki67 gene sites but not
ID1 gene sites (C, G, K). ‘‘M’’ denotes Mock transfection control. ‘‘A3’’ and ‘‘C2’’ denote MAGE-A3 and MAGE-C2, respectively.
doi:10.1371/journal.pone.0023747.g002
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believed to play a role in proliferation and regulation of the cell
cycle [21] and we and others have shown that MAGE expression
affects the cell cycle [10,12]. We found that KAP1 occupancy of
these sites was very low in control vector transfected cells but
increased significantly with expression of MAGE-A3 or MAGE-
C2 (p,0.05), indicating MAGE enhances KAP1 mediated
binding to Ki67 (Figure. 2E, 2I). We also found increased
H3me3K9 (p,0.05), indicating transcriptionally inactive hetero-
chromatin induced by KAP1 (Figure. 2F, 2J). MAGE-A3 and
MAGE-C2 each bound to both KAP1 binding sites, co-localizing
with KAP1, as would be predicted from the known ability of
MAGE I to bind KAP1(Figure. 2G, 2K) [11,13] Finally, as we
would predict from the increased binding of KAP1 and increased
chromatin compaction, Ki67 mRNA (p,0.01) and protein
expression were decreased by MAGE I (Figure. 2H, 2L).
Mutant MAGE I does not induce KAP1 mediated gene
regulation
To determine whether MAGE I mediated gene regulation
requires MAGE I - KAP1 binding, we repeated ChIP and mRNA
expression experiments with ectopic over-expression of mutant
MAGE-C2
L152A,L153A, which has decreased ability to bind KAP1,
and specifically abrogates MAGE I mediated substrate ubiquitination
by KAP1 E3 ligase [13]. We found that KAP1 remains bound to the
ID1 gene in HEK293T cells expressing ectopic MAGE-C2
L152A,L153A
and is tightly associated with H3me3K9 compared to cells with wild
Figure 3. MAGE-C2 mutant fails to regulate KAP1 gene binding, H3me3K9, and gene repression in HEK293T cells. MAGE-C2
L152A L153A
expression does not affect binding of KAP1, H3me3K9, and repression of the ID1 tumor suppressor gene (A, B, D). MAGE-C2
L152A L153A enrichment is
seen at ID1 sites compared to MAGE-C2 and mock negative control (C). MAGE-C2
L152A L153A expression dose not increases binding of KAP1, H3me3K9,
and repression of mRNA level of the Ki67 gene (E, F, H, I, J). Note MAGE-C2
L152A L153A fails to bind to the Ki67 gene sites but ID1 gene sites (C, G, K).
‘‘M’’ denotes Mock transfection control. ‘‘C2’’ denotes MAGE-C2. ‘‘MC’’ represents MAGE-C2
L152A L153A.
doi:10.1371/journal.pone.0023747.g003
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did not see an increase of ID1 mRNA (Figure. 3D). Interestingly,
although it does not induce ZNF382 ubiquitination, MAGE-
C2
L152A,L153A is still somewhat localized to the ID1gene (Figure 3C)
raising the possibility that it retains residual capacity to bind KAP1
or another protein in the KAP1/chromatin complex (Figure 4).
This result supports the hypothesis that MAGE I specifically
mediates de-repression by altering KZNF ubiquitination and
degradation. MAGE-C2
L152A,L153A fails to enhance KAP1 and
H3me3K9 binding to Ki67 gene (Figure. 3E, I, F, J), and MAGE-
C2
L152A,L153A does not bind to Ki67 gene (Figure. 3G, 3K).
Predictably, Ki67 mRNA expression is not decreased by expression
of MAGE-C2
L152A,L153A (Figure 3H). Overall, these results show
that proper binding of MAGE I to KAP1 is required for MAGE l
mediated gene regulation and implicate ubiquitination in the
mechanism, but leave open the possibility that MAGE I may have
other interactions with KAP1-chromatin complexes.
MAGE-C2 enhances-ZNF382 ubiquitination
It is known that MAGE I enhances KAP1 ubiquitin ligase
activity and specifically increases ubiquitination and degradation
of p53 [13]. To determine whether MAGE could alter KAP1
localization by increasing ubiquitination and degredation of a
KZNF, we investigated ZNF382 ubiquitination in the presence of
wild type and mutant MAGE-C2. MAGE-C2 expression en-
hanced ZNF382 ubiquitination and degradation in an in vivo
ubiquitination reaction (Figure 4). ZNF382 poly-ubiquitination
requires MAGE-C2 binding to KAP1, since non-binding mutant
MAGE-C2
L152A,L153 A does not increase ZNF382 ubiquitination.
Because binding to KAP1 is necessary for KZNF suppression of
specific genes, these results suggest that MAGE-C2 may prevent
significant repression of a KZNF target gene by increasing
ubiquitination and degradation of KZNFs that bind to that gene.
Discussion
The nearly tumor specific expression patterns of MAGE I
proteins make them ideal therapeutic targets, and clinical and in
vitro evidence is accumulating that MAGE I expression contributes
to cancer chemoresistance and growth, cell survival, and
metastasis [1,5,6,7,8,9]. We and others have previously shown
that common functions of MAGE are to bind to KAP1 and
suppress p53 [9,10,13] but the biochemical functions of MAGE I
proteins remain incompletely understood. In the present work we
demonstrate that MAGE I expression can regulate ZNF382, an
important KZNF tumor suppressor, and can affect the ability of
ZNF382 and KAP1 to bind and regulate a downstream target, the
ID1 oncogene. MAGE expression suppresses ZNF382 function,
decreasing KAP1 binding to ID1 and promoting ID1 expression,
in line with previously observed pro-oncogenic effects of MAGE I.
We also show MAGE I can affect KAP1 binding to the Ki67 gene,
with seemingly opposite effects, including increased KAP1
binding, increased chromatin compaction, and decreased gene
expression. Additionally, MAGE-C2
L152A,L153A fails to regulate
gene expression, indicating that proper binding between MAGE I
and KAP1 is required for MAGE I regulation of gene expression.
ZNF382 is a tumor suppressor that is ubiquitously expressed in
normal tissues, where it recruits KAP1 and causes chromatin
compaction and suppression of several oncogenes including ID1
[16]. Expression of ZNF382 has been reported to be lost in cancers
due to gene deletion or hypermethylation, but ZNF382 expression
and tumor suppression are expected in hypomethylated states
[16]. Hypomethylated states support MAGE I expression, and our
data show unequivocally that MAGE I can suppress ZNF382
function, thereby relieving repression of ZNF382 downstream
targets and inducing oncogene expression. Thus, MAGE I
expression offers a mechanism for ZNF382 suppression and
oncogene activation in the absence of DNA hypermethylation or
ZNF382 gene deletion.
It has been shown that MAGE I enhances E3 ubiquitination of
p53 by increasing KAP1 ubiquitin E3 ligase activity through
recruitment and/or stabilization of E3 ubiquitin-conjugating
cascades [13]. Our data show that MAGE I induces ubiquitination
and degradation of ZNF382 and that binding of MAGE to KAP1
is required, suggesting that MAGE I can also increase KAP1
ubiquitination of KZNFs. However, other possible mechanisms
such as ubiquitin receptor modification or interference with the
assembly of the basal transcription apparatus by the ubiquitin
moiety itself cannot be completely excluded [13,22]. While it
appears clear that MAGE I can decrease KAP1 binding in the
case of the ID1 gene, probably by increasing ubiquitination and
degradation of KZNF382, there are at least two other potential
mechanisms by which MAGE I could affect KAP1 localization
and gene repression. Since both MAGE I and KZNF proteins
bind to the KAP1 RBCC region, overlap or close proximity of the
Figure 4. MAGE–KAP1 binding induces ZNF382 ubiquitination
in HEK293T cells. HEK293T cells were transiently transfected
with His tagged wild-type MAGE-C2 (WT), mutant (non-binding) MAGE-
C2
L152A L153A , or empty vectors (Mock) and co-transfected with ZNF382,
KAP1, and HA tagged ubiquitin. Cells were incubated for 5 hours in the
presence of 25 mM MG132 (C2211, SIGMA). Top two panels: ZNF382
(around 55 kDa), MAGE-C2 (around 50 KD) and KAP1 (110 KD) were
detected in whole lysates by immunoblotting with anti-KAP1 (upper
panel) and anti-FLAG antibodies (lower panel). Third panel: His tagged
ubiquitinated proteins were immunoprecipitated with anti-His and
detected with anti-HA. High-molecular-weight ubiquitinated species were
seen only in blots of cells transfected with both ZNF382 and MAGE-C2.
Note that no ubiquitination occurred when wild type MAGE-C2 was
replaced withMAGE-C2
L152A L153A whichdoes not bind toKAP1,indicating
MAGE–KAP1 binding is required for ZNF382 ubiquitination. Also please
note an ubiquitinated ZNF382 degradation product of lesser molecular
weight in the presence of wild type MAGE-C2 and KAP1. Lowest panel:
immunoprecipitationandimmunoblotting confirms expression of ZNF382.
doi:10.1371/journal.pone.0023747.g004
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competition, with decreased KZNF binding to KAP1 leading to
decreased KAP1 recruitment to specific sites. Alternatively,
MAGE I expression may stabilize binding between KZNFs and
KAP1 without increasing ubiquitination, a situation which fits the
data observed for Ki67 where we see increased binding of KAP1
associated with MAGE I binding to the same site, presumably
mediated by an unknown KZNF. The fact that MAGE I protein
co-localizes with KAP1 to Ki67 supports this model.
It is important to note that the effects of MAGE-A3 and MAGE-
C2 are thus far always similar for a given gene and do not appear to
be random, indicating a true biologic effect. Since both MAGE-A3
and MAGE-C2 have similar effects on each of the genes studied (i.e.,
decreased KAP1 binding of ID1 and increased KAP1 binding to
Ki67) the reason for the opposite effects does not appear likely to
reside in the MAGE I proteins and is more likely a function of the
particular KZNF. KZNFs bind KAP1 by their KRAB domains,
which are heterogeneous and may contain members of one or both of
several KRAB A and KRAB B motifs [23]. We speculate that
different KRAB domains may bind to KAP1 with differing affinities
or at slightly different sites, or may interact with the ubiquitin ligase
complexes in different ways, leading either to increased KZNF
ubiquitination and decreased binding seen with ID1,o rt oi n c r e a s e d
binding and co-localization with MAGE I seen with Ki67.E x c e p tf o r
sites of DNA damage, where KAP1 binds DNA in a sequence
independent fashion, KAP1 normally requires binding to KZNFs to
guide it to specific genes. KAP1 binds to ,7,000 sites in the human
genome [20] and there are about 270 KZNFs, indicating that some
KZNFs must bind to more than one site. Unfortunately, antibodies
are not available for most KZNFs and it is not known where most of
them bind, making it problematic and beyond the scope of this work
to completely analyze their regulation and function, and thus identify
the KZNFs that bind to Ki67. While the results with Ki67 seem to
indicate an anti- proliferative affect of MAGE I proteins, it is
important to consider the role of MAGE I in the DNA damage
response, which requires a temporary pause in the cell cyclefor DNA
repair. Interestingly, when looked at over the course of 72 h we saw
an initial drop in Ki67 expression followed by slow partial recovery,
compatiblewith a temporary cellcyclehalt (data not shown).While it
remainstobedeterminedhowMAGEIregulationofKi67 mayaffect
overall cell proliferation or DNA damage repair, when these data are
combined with our studies of ZNF382 they show unequivocally that
MAGE I proteins may have differential effects (repression or de-
repression) on different KAP1 KZNF targets.
Because transmission of signals in biologic systems may be
complex and intertwined, it is often problematic to assign a direct
causal relationship to regulation of specific genes by an individual
molecule or sets of molecules. Genes in areas of chromatin
relaxation may still be negatively regulated by other mechanisms,
so removal of KAP1 mediated repression by MAGE I expression
does not guarantee protein expression. However, the ability of
KZNF targeted KAP1 to suppress specific genes by causing
localized chromatin condensation trumps other forms of regula-
tion because if the gene is condensed, it cannot be transcribed.
Therefore, our finding that MAGE I expression affects KAP1
binding and chromatin condensation unequivocally defines direct
gene regulation by MAGE I proteins (Figure 5).
Materials and Methods
Tissue culture and transfections
HEK293T were purchased from American Type Culture
Collection and were cultured in DMEM with 10% fetal bovine
serum and 1% antibiotics (penicillin, streptomycin). CHO-5xGal4-
UAS-TK-Luc-2p cells were cultured in F12 with 10% fetal bovine
serum and 100 ug/ml hygromycin antibiotic [18,19]. For
transfections with MAGE-A3 or C2, we used calcium phosphate
(Invitrogen) and Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s recommendations.
RNA isolation, reverse transcription and qRT-PCR
RNA from cells was isolated using a total RNA isolation mini kit
(Qiagen). Total RNA was treated with 2 units of DNase I (New
England Biolabs). Reverse transcription and qRT-PCR were
Figure 5. Proposed model of MAGE-KAP1 interactions. KAP1 performs diverse functions by serving as a molecular scaffold that binds multiple
proteins which allow it to regulate chromatin environments. KAP1 has an N terminal RING-B-box coiled-coil (RBCC) domain that binds to the KRAB
domains of KZNFs, which target KAP1 to specific DNA sequences through their zinc finger DNA binding motifs. KAP1 mediates localized compaction
of euchromatin to heterochromatin that is necessary for suppression of specific gene transcription, and that is associated with chromatin
modifications including histone de-acetylation, histone 3 tri-methylation on K9, and HP1 binding to both DNA and histones. In some cases, MAGE
expression enhances KAP1 E3 ubiquitin ligase activity, resulting in KZNF ubiquitination and degradation, thereby de-repressing KZNF mediated gene
repression, shown as (-). In other cases, MAGE enhances KZNF and KAP1 localization to specific gene loci, shown as (+) (After A. Ivanov [22]).
doi:10.1371/journal.pone.0023747.g005
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SYBR Green Core PCR reagents (SABiosciences), according to
manufacturer’s recommendations. Quantification of qRT-PCR
was done using an ABI Prism 7000 machine and ABI Prism 7000
SDS software (Applied Biosystem). Sequences of primers used for
qRT-PCR are presented in Table 1.
Protein isolation
To obtain the whole-cell lysate for western blot analysis, cells
were lysed using denaturing RIPA buffer containing phosphate
buffer saline (pH 7.4), 0.5% sodium deoxycholate, 0.1% SDS, 1%
(v/v) NP-40, 100 mM sodium orthovanadate, and proteinase
inhibitor cocktail (Sigma).
Antibodies
For human target validation studies and immunoprecipitation
we used: anti–MAGE-C2 (polyclonal, Santa Cruz Biotechnology),
anti-human KAP1 (polyclonal, Novus Biologicals, recognizing the
NH2-terminal region 1–50 amino acids of KAP1), anti-KAP1
monoclonal 20C1 (ChIP grade, Abcam), anti-FLAG monoclonal
M2 (Sigma) and anti-human H3me3K9 (monoclonal, E6204,
SABiosciences), and anti-human Ki67 (polyclonal, ab15580,
Abcam).
Expression vectors
FLAG-tagged wild type or mutant MAGE-A3 or C2 were
expressed using p3xFLAG-CMV-2 plasmid (Sigma). ZNF382 with
His tag at the 39 end was also used in this vector.
Site-Directed Mutagenesis
Site-directed mutagenesis was done by overlap extension PCR
(Invitrogen). MAGE-C2 mutation: L152A, L153 A. The primers
including 50 forward ( GGT GGC CGA GTT AGT GGA GTT
CGC AGC ACT CAA ATA CGA AGC AGA GGA GC) and 50
reverse (GCT CCT CTG CTT CGT ATT TGA GTG CTG
CGA ACT CCA CTA ACT CGG CCA CC) were used to allow
substitutions L152A and L153A in the MHD region of MAGE-
C2. MAGE-A3- L120A, L121A was introduced using the primers
50 forward (GGT GGC CGA GTT GGT TCA TTT TGC AGC
ACT CAA GTA TCG AGC CAG GGA GC) and 50 reverse
(GCT CCC TGG CTC GAT ACT TGA GTG CTG CAA AAT
GAA CCA ACT CGG CCA CC). PCR conditions included one
cycle at 94uC for five minutes and 30 cycles of: 94uC for 30 sec,
60uC for 30 sec and 72uC for 30 sec, followed by one cycle of
72uC for seven minutes. PCR products were run on an agarose gel
to confirm the presence of a product of correct molecular weight.
Sequencing was performed to confirm the mutagenesis.
Mammalian Two-Hybrid assay
Mammalian two hybrid studies were performed after modifica-
tion of the Matchmaker
TM system (Clontech Laboratories Inc),
essentially according to the instructions of the manufacturer, with
SEAP secreted reporter protein. The modified bait expression
plasmid contains an SV40 promoter driving expression of a hybrid
of full length (FL) or MHD MAGE-A3 or C2 and a DNA-binding
domain (DBD). The modified prey expression plasmid uses the
SV40 promoter driving a hybrid protein of an activation domain
(AD) and FL or RBCC region KAP1. Binding of the bait and prey
plasmids cis-activates E1b which in turn transactivates a reporter
plasmid containing a secreted alkaline phosphatase (SEAP) cDNA.
Phosphatase produced by the transactivated SEAP plasmid is
measured by enzyme-based detection using the chemiluminescent
substrate CSPD.
Chromatin immunoprecipitation
ChIP assays were performed according to the protocol of the kit
manufacturer (SABiosciences). Equal amounts of specific and
nonspecific control IgG were used. Both input DNA and
immunoprecipitated DNA were purified with SABiosciences
DNA mini kit. All samples were analyzed by qRT-PCR and were
carried out in triplicate with primers specific for these regions
using SYBR Green Supermix (SABiosciences). The fold enrich-
ment of target sequence was determined using the following
formula: fold enrichment =2
(DCT of input 2 DCT of IP’ed DNA).
Luciferase reporter assay
To test how MAGE I affects ZNF382, CHO cells with a
ZNF382 luciferase reporter 5xGal4-UAS-TK-Luc-2p were eval-
uated after transfected with ZNF382 with or without MAGE-A3
or C2 or mutants. Luciferase assay was done as previously
described [18,19]. All the experiments were performed in
triplicates.
In vivo ubiquitination assay
8 mg of wild-type or mutant MAGE-C2 or mutant expression
plasmids, or empty vector control, were introduced into
HEK293T cells at 70% confluency using the CaPO4 method
(Clotech). 8 mg FLAG-ZNF382-His tag, 4 mg KAP1, 4 mgo f
pcDNA 3.1+ vector harboring HA tagged ubiquitin were co-
transfected. After 20 h, the cells were treated with 25 mMo f
MG132 (C2211, Sigma) for 5 h, lysed in RIPA buffer, and
subjected to immunoprecipitation. A 500 mg aliquot of total
protein from the transfected HEK293T cells in 250 ml lysis
solution was mixed with 10 ml of the anti-His affinity matrix (Cell
signaling) pre-blocked with 2% bovine serum albumin (BSA), and
incubated overnight with gentle rotation at 4uC. The affinity
matrix was washed with HIPA buffer three times, collected by
centrifugation, and the precipitated proteins were denatured in
sample buffer containing 0.1 M dithiothreitol (DTT), subjected to
7% SDS-PAGE and transferred to a PVDF membrane. The
transferred proteins were then incubated with anti-His (high
affinity HA 3F10, Cell signaling), or anti-HA (monoclonal, Cell
signaling) antibodies. Anti-mouse IgG, HRP-linked secondary
antibodies (Cell signaling) were used for the western blotting
procedure.
Table 1. Real time PCR primers for target gene screening.
Primer name Sequence (59 R 39) Size
KAP1 Binding on Ki67-1F CTCCGTCTGTGGCACGGGAA 108 bp
KAP1 Binding on Ki67-1R TGCCGGCACTGTACCGAGC
KAP1 Binding on Ki67-2F CCCTGCCTGACAGGAACACGC 70 bp
KAP1 Binding on Ki67-2R GCGCTACTGTGGAGCTGGGG
KAP1 Binding on ID1-1F TGCAGGTTTGGCCTATGCTGAG 103 bp
KAP1 Binding on ID1-1R AAAGGGCCATTGCTGCCCAGG
Ki67-1F TTGGAGAATGACTCGTGAGC 218 bp
Ki67-1R GGAAGCTTTCAATGACAGGA
ID1-1F TGGAGATTCTCCAGCACGTC 181 bp
ID1-1R ATGCGATCGTCCGCAGGAAC
GAPDH-1F GAGTCAACGGATTTGGTCGT 238 bp
GAPDH-1R TTGATTTTGGAGGGATCTCG
doi:10.1371/journal.pone.0023747.t001
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